On Monday, Shares of Encana Corp (USA) (NYSE:ECA), added 2.12% and closed at $11.09 in the last trading session. The last trading range of the stock ranges between $11.05 and $11.31. The company’s Market capitalization is $10.92 Billion with the total Outstanding Shares of 972.94 million. During the 52-week trading session the minimum price at which share price traded, registered at $3.00 and reached to max level of $11.31. At recently’s Shareholder Day being held in New York City, Encana’s President & CEO Doug Suttles together with members of the executive and administration teams will outline the company’s five-year, quality growth potential.
The event will include a review of the company’s world-class core four assets which contain an inventory of about 10,000 premium return well locations.
Encana will outline its relentless focus on growing value over the next five years counting a potential 300 percent increase in cash flow, a doubling of corporate margins, a 60 percent increase in total production and achieving a balanced production mix of oil and liquids and natural gas.
The company’s growth potential is underpinned by active and disciplined balance sheet administration. The company has access to over $5 billion in liquidity, a robust hedging program and a 100 percent short-cycle capital program. The presentation will also highlight Encana’s culture of innovation and efficiency.
Clovis Oncology Inc (NASDAQ:CLVS), jumped 10.30% and closed at $32.44 in the last trading session. The last trading range of the stock ranges between $27.84 and $32.98. The company’s Market capitalization is $1.03 Billion with the total Outstanding Shares of 38.50 million. During the 52-week trading session the minimum price at which share price traded, registered at $11.57 and reached to max level of $109.18. Clovis Oncology (CLVS) declared recently the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen. Rucaparib is presently under priority review with FDA for the monotherapy treatment of advanced ovarian cancer in patients with BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations who have been treated with two or more chemotherapies, and the submission has a PDUFA date of February 23, 2017.
Rucaparib is the Company’s oral, small molecule inhibitor of PARP1, PARP2 and PARP3 presently being developed for the treatment of ovarian cancer, specifically in patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, counting those with high genomic loss of heterozygosity (LOH) also known as “BRCA-like.” The current NDA submission seeks approval in patients with tumor BRCA mutations, which includes both germline and somatic mutations.
“These results demonstrate that rucaparib may represent an important option for women with multiply relapsed BRCA-mutated ovarian cancer based on its encouraging efficacy and tolerability,” said Rebecca S. Kristeleit, MD, PhD, The University College London, Cancer Institute, London, UK. “In my opinion, rucaparib has the hallmarks of an important new therapeutic option for ovarian cancer patients.”